{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:26:04Z","timestamp":1787509564434,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["patient-research.elsevier.com","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ctrv.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T16:31:09Z","timestamp":1400257869000},"page":"857-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Systemic therapy in neurofibromatosis type 2"],"prefix":"10.1016","volume":"40","author":[{"given":"Stephanie Hui-Su","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ardern-Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"McCowage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6429","key":"10.1016\/j.ctrv.2014.05.004_b0230","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2014.05.004_b0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otology & neurotology: official publication of the American Otological Society","volume":"26","author":"Evans","year":"2005","journal-title":"Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.05.004_b0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet Part A"},{"issue":"304","key":"10.1016\/j.ctrv.2014.05.004_b0020","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Quart J Med"},{"issue":"9679","key":"10.1016\/j.ctrv.2014.05.004_b0025","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ctrv.2014.05.004_b0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","article-title":"Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]","volume":"11","author":"Evans","year":"2009","journal-title":"Genet Med: Off J Am Coll Med Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2014.05.004_b0035","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1148\/radiology.218.2.r01fe40434","article-title":"Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype","volume":"218","author":"Patronas","year":"2001","journal-title":"Radiology"},{"issue":"21 Suppl 1","key":"10.1016\/j.ctrv.2014.05.004_b0040","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/01.wnl.0000435743.49414.b6","article-title":"Achieving consensus for clinical trials: the REiNS international collaboration","volume":"81","author":"Plotkin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ctrv.2014.05.004_b0045","doi-asserted-by":"crossref","unstructured":"Neurofibromatosis. Conference statement. National institutes of health consensus development conference. Arch Neurol, vol. 45(5), 1988. p. 575\u201378. [Epub 1988\/05\/01].","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"10.1016\/j.ctrv.2014.05.004_b0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): a clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.ctrv.2014.05.004_b0055","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/513207","article-title":"Germline mutation of INI1\/SMARCB1 in familial schwannomatosis","volume":"80","author":"Hulsebos","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2014.05.004_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0165-4608(99)00201-0","article-title":"Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas","volume":"118","author":"Hung","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"10.1016\/j.ctrv.2014.05.004_b0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2443.2001.00432.x","article-title":"Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma","volume":"6","author":"Kino","year":"2001","journal-title":"Genes Cells Dev Mol Cell Mech"},{"issue":"3","key":"10.1016\/j.ctrv.2014.05.004_b0070","first-page":"529","article-title":"Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities","volume":"59","author":"Parry","year":"1996","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.ctrv.2014.05.004_b0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrneurol.2011.82","article-title":"Emerging therapeutic targets in schwannomas and other merlin-deficient tumors","volume":"7","author":"Ammoun","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.05.004_b0080","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.febslet.2012.03.016","article-title":"Merlin, a multi-suppressor from cell membrane to the nucleus","volume":"586","author":"Zhou","year":"2012","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.ctrv.2014.05.004_b0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.spen.2006.01.007","article-title":"The genetic and molecular pathogenesis of NF1 and NF2","volume":"13","author":"Yohay","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.ctrv.2014.05.004_b0245","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","author":"Blakeley","year":"2011","journal-title":"Am J Med Genet Part A"},{"issue":"2","key":"10.1016\/j.ctrv.2014.05.004_b0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MAO.0b013e318241c086","article-title":"Conservative management versus stereotactic radiation for vestibular schwannomas: a meta-analysis of patients with more than 5 years\u2019 follow-up. Otology & neurotology: official publication of the American Otological Society","volume":"33","author":"Maniakas","year":"2012","journal-title":"Am Neurotol SocEur Acad Otol Neurotol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.05.004_b0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1215\/15228517-2007-027","article-title":"Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature","volume":"9","author":"Balasubramaniam","year":"2007","journal-title":"Neuro-Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2014.05.004_b0105","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/1097-0142(197705)39:5<1955::AID-CNCR2820390507>3.0.CO;2-F","article-title":"Combination chemotherapy of metastatic malignant schwannoma with vincristine, adriamycin, cyclophosphamide, and imidazole carboxamide: a case report","volume":"39","author":"Goldman","year":"1977","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2014.05.004_b0110","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2014.05.004_b0115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otology & neurotology : official publication of the American Otological Society","volume":"29","author":"Clark","year":"2008","journal-title":"Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.05.004_b0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ncponc1157","article-title":"Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy","volume":"5","author":"Plotkin","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2014.05.004_b0250","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otology & neurotology: official publication of the American Otological Society","volume":"31","author":"Plotkin","year":"2010","journal-title":"Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"9","key":"10.1016\/j.ctrv.2014.05.004_b0130","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ctrv.2014.05.004_b0255","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","author":"Karajannis","year":"2013","journal-title":"Neuro-Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2014.05.004_b0140","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.05.004_b0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/13543784.2013.772979","article-title":"Optimizing biologically targeted clinical trials for neurofibromatosis","volume":"22","author":"Gutmann","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"21 Suppl 1","key":"10.1016\/j.ctrv.2014.05.004_b0150","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/01.wnl.0000435748.79908.c5","article-title":"Conclusions and future directions for the REiNS international collaboration","volume":"81","author":"Widemann","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ctrv.2014.05.004_b0260","doi-asserted-by":"crossref","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.ctrv.2014.05.004_b0160","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1593\/neo.11356","article-title":"Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin","volume":"13","author":"Laulajainen","year":"2011","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.ctrv.2014.05.004_b0165","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.ejca.2009.03.013","article-title":"Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells","volume":"45","author":"Lee","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2014.05.004_b0170","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2004-07-2967","article-title":"Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance","volume":"105","author":"Tseng","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2014.05.004_b0175","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/1535-7163.MCT-11-0243","article-title":"Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways","volume":"10","author":"Angelo","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.ctrv.2014.05.004_b0180","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/0008-5472.CAN-07-5849","article-title":"Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma","volume":"68","author":"Ammoun","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2014.05.004_b0185","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2","volume":"13","author":"Ammoun","year":"2011","journal-title":"Neuro-Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.05.004_b0190","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate)","volume":"69","author":"Mukherjee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.05.004_b0265","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-010274","article-title":"Imatinib in neurofibromatosis type 2","author":"Lim","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2014.05.004_b0270","doi-asserted-by":"crossref","DOI":"10.1227\/01.neu.0000333303.79931.83","article-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II","volume":"62","author":"Harris","year":"2008","journal-title":"Neurosurgery"},{"issue":"9","key":"10.1016\/j.ctrv.2014.05.004_b0205","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/neuonc\/nor072","article-title":"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas","volume":"13","author":"Bush","year":"2011","journal-title":"Neuro-Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2014.05.004_b0210","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","article-title":"Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors","volume":"70","author":"Wong","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.05.004_b0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"New England J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2014.05.004_b0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro-Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.05.004_b0275","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otology & neurotology: official publication of the American Otological Society","volume":"33","author":"Plotkin","year":"2012","journal-title":"Am Neurotol Soc Eur Acad Otol Neurotol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T11:03:48Z","timestamp":1565435028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0305737214000899"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.05.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy in neurofibromatosis type 2","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}